These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 24511544)
1. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544 [TBL] [Abstract][Full Text] [Related]
2. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
3. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis. Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408 [TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. Khan I; Waqas M; Shamim MS J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762 [TBL] [Abstract][Full Text] [Related]
7. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544 [TBL] [Abstract][Full Text] [Related]
8. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. Chaurasia A; Park SH; Seo JW; Park CK J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330 [TBL] [Abstract][Full Text] [Related]
10. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605 [TBL] [Abstract][Full Text] [Related]
11. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340 [TBL] [Abstract][Full Text] [Related]
12. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690 [TBL] [Abstract][Full Text] [Related]
13. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study. Paldor I; Drummond KJ; Kaye AH J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495 [TBL] [Abstract][Full Text] [Related]
14. Cystic glioblastoma: an evaluation of IDH1 status and prognosis. Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051 [TBL] [Abstract][Full Text] [Related]
15. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor. Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929 [TBL] [Abstract][Full Text] [Related]
16. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165 [TBL] [Abstract][Full Text] [Related]
17. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977 [TBL] [Abstract][Full Text] [Related]
19. R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme. Yalaza C; Ak H; Cagli MS; Ozgiray E; Atay S; Aydin HH Ann Clin Lab Sci; 2017 May; 47(3):362-364. PubMed ID: 28667042 [TBL] [Abstract][Full Text] [Related]
20. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]